一年一度的美国血液学会（ASH）年会作为全球血液学领域最负盛名的国际学术盛会之一，历年来备受瞩目，每年均吸引着全球范围内众多顶尖专家学者共襄盛举。2024年，第66届ASH年会定于12月7日-10日在美国圣迭戈召开。此次年会不仅将作为全球血液学研究的璀璨舞台，公布一系列顶尖的研究摘要，引领学术前沿，更将深度聚焦如何优化患者管理与治疗策略，以及探索创新的治疗途径，为血液学领域的发展注入新的活力。本届ASH年会提交的摘要数量再创历史新高，多达7950余篇佳作被接纳，充分彰显了全球血液学研究领域的蓬勃生机与无限潜力。
尤为值得一提的是，近年来，中国在临床研究领域的迅猛崛起，不仅推动了国内血液学研究的快速发展，更显著提升了中国在全球血液学领域的影响力与话语权。根据ASH官网于当地时间11月5日上午9:00公布的最新摘要信息，医脉通小编检索到今年共有75篇中国专家汇报的研究入选Oral Abstracts，再创新高。这一数字不仅彰显了我国血液学研究的卓越成就，更预示着中国学者在国际舞台上的影响力正持续增强。
医脉通特将此次入选的75篇研究相关信息进行了整理，旨在为广大读者呈现一场精彩纷呈的学术盛宴，让我们共同见证中国血液学研究在全球舞台上的辉煌时刻。
标题：Rbm38 Regulates Heme Biosynthesis Via Fine-Tuning the RNA Alternative Splicing, Stability and Translation of Porphyrin Metabolic Enzyme Gene Ferrochelatase (Fech)
报告人及单位：Yang Mei，湘潭市中心医院
标题：Clec16a-Mediated Mitophagy Modulates Zebrafish Definitive Hematopoiesis
报告人及单位：Shuyang Cai，上海中医药大学附属市中医医院
标题：The TFG-ROS1 Fusion Is an Oncogenic Driver of Human Myeloid Leukemia
报告人及单位：Jie Sun，浙江大学医学院附属第一医院
标题：Targeting PRMT9 Overcomes Venetoclax Resistance in AML By Modulating Splicing and Inhibiting Translation
报告人及单位：Yang Li，福建医科大学附属协和医院
标题：Targeted-Delivery Strategy of Engineered EV Functionalized By Anti-CD3/CD19 Bi-Specific T-Cell Engager in Treating B-Cell Malignancies
报告人及单位：杨秀秀，中国医学科学院血液病医院（中国医学科学院血液学研究所）
标题：Rituximab, Lenalidomide, and Zanubrutinib (ZR2) with Sequential CAR-T Cell As First-Line Therapy for High-Risk Large B Cell Lymphoma
报告人及单位：Mingming Zhang，浙江大学医学院附属第一医院
标题：IL-10 Expressing CD19 CAR-T Cells Induce Complete Remission and Improve Long-Term Protection in Relapsed or Refractory B-Cell Hematological Malignancies
报告人及单位：Jingjing Ren，深圳莱芒生物科技有限公司
标题：JAK/Rock Inhibitor Rovadicitinib for Glucocorticoid-Refractory or -Dependent Chronic Graft-Versus-Host Disease：Updated Results of Multicenter, Phase 1b/2a Trial
报告人及单位：赵妍敏，浙江大学医学院附属第一医院
标题：A Phase II Study to Evaluate the Efficacy and Safety of Pimicotinib (ABSK021) in Chronic Graft Versus Host Disease (cGvHD) after 1 or More Lines of Systemic Treatment
报告人及单位：吴德沛，苏州大学附属第一医院
标题：Multiomic Analyses Uncover Immune Signatures of Steroid-Refractory Graft-Versus-Host Disease
报告人及单位：Zengkai Pan，上海交通大学医学院附属瑞金医院
标题：Imbalanced Expression of TACI Isoforms Regulated By TNFRSF13B Variants Promotes the Progression of Epstein-Barr Virus-Associated Lymphoproliferative Diseases
报告人及单位：Xinyue Deng，华中科技大学同济医学院附属同济医院
标题：Efficient Generation of CAR-T By the First Coacervate-Based Gene Delivery System
报告人及单位：Peipei Zhu，西湖大学
标题：Potent in Vitro and In Vivo Efficacy of Hdz-C123A, a GSPT1 Degrader-Antibody Conjugate Targeting CD123 in Acute Myeloid Leukemia
报告人及单位：Yu Guo，浙江大学（杭州）创新医药研究院
标题：Reconstruction of Megaloblastic Anemia in a Novel Erythroblastic Island Humanized Mouse Model with Mature Circulating Human Red Blood Cells
报告人及单位：Shuang Liu，南京大学化学和生物医药创新研究院
标题：Exploring the Mechanism of Chromatin Spatial Structure Changes and Transcriptional Regulation in Age-Related Clonal Hematopoiesis Caused By DNMT3A Mutations Using Chromatin Capture Technology
报告人及单位：Yujun Dai，中山大学肿瘤防治中心
标题：Prospective Study of Avapritinib in Patients with Relapsed/Refractory or MRD-Positive Core-Binding Factor Acute Myeloid Leukemia with KIT Mutations
报告人及单位：Xueqing Dou，苏州大学附属第一医院
标题：Targeting the Hypoxic Microenvironment in Cutaneous Chronic Graft-Versus-Host Disease through PI3Kδ Inhibition
报告人及单位：Yuxi Xu，陆军军医大学第二附属医院（新桥医院）
标题：Elevated Dosing of Recombinant Human Thrombopoietin Accelerates Platelet Engraftment in Allogeneic Hematopoietic Stem Cell Transplantation: A Prospective, Dosage-Optimization, Controlled Clinical Study
报告人及单位：Dan Feng，中国医学科学院血液病医院（中国医学科学院血液学研究所）
标题：Epstein-Barr Virus Reactivation and Post-Transplant Lymphoproliferative Disorders after Allo-HSCT in the Era of Letermovir for Cytomegalovirus Prophylaxis
报告人及单位：Jingtao Huang，上海血液学研究所
标题：Safety and Efficacy of VA Combined with Modified BuCy Conditioning Regimen Followed By Allo-HSCT for High-Risk or Refractory/Relapsed Acute Lymphoblastic Leukemia : A Prospective, Single-Center, Single-Arm Clinical Trial
报告人及单位：Xiaoqian Chen，苏州大学附属第一医院
标题：Effects of Low-Molecular-Weight Heparin on Pregnancy Outcomes in Protein S Deficiency: A Prospective, Randomized Controlled Phase II Clinical
报告人及单位：臧梦桐，北京大学人民医院
标题：Hetrombopag Added to Immunosuppressive Therapy in First-Line Treatment of Severe Aplastic Anemia: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial
报告人及单位：张凤奎，中国医学科学院血液病医院（中国医学科学院血液学研究所）
标题：Efficacy and Safety of Adding Blinatumomab to First-Line Treatment for Chinese Children with B-Cell Acute Lymphoblastic Leukemia
报告人及单位：Ruidong Zhang，首都医科大学附属北京儿童医院
标题：Integrative Multi-Omics Analyses Identify a High-Risk Subgroup of Patients with Poor Prognosis in t(8;21) Acute Myeloid Leukemia
报告人及单位：Yu Liu，中国医学科学院血液病医院（中国医学科学院血液学研究所）
标题：Mitochondrial Transcriptional-Translational Conflict Contributes to Defective Erythropoiesis and Disease Progression in Splicing Factor Mutant Myelodysplastic Syndromes
报告人及单位：李巧利，中国医学科学院血液病医院（中国医学科学院血液学研究所）
标题：Modified Dual CLL1-CD15 and CLL1-CD16 Icar-T Cells for Mitigating Granulocytopenia Toxicities in the Treatment of Acute Myeloid Leukemia
报告人及单位：Rui Zhang，天津市第一中心医院
标题：A Multi-Center Clinical Trial of Allogeneic Hematopoietic Stem Cell Transplants in Transfusion Dependent Thalassemia
报告人及单位：刘容容，广西医科大学第一附属医院
标题：A Single-Cell Transcriptomic Atlas of Cytokine Storm in CAR-T Therapy, COVID-19, and SLE
报告人及单位：Xia Li，浙江大学医学院附属第一医院
标题：β2-Adrenergic Receptor Agonist Terbutaline Regulates Macrophage Polarization Via HMGB1 in Immune Thrombocytopenia
报告人及单位：郭秋雨，北京大学人民医院
标题：Differentiation Route Generates Functional Biased Platelets and Responses Distinctly to Varying Physiological Demands
报告人及单位：Jingkun Liu，中国科学院北京基因组研究所（国家生物信息中心）
标题：ERAD Activity Distinguishes the Functional Heterogeneity of Hematopoietic Stem Cells
报告人及单位：QinLu Peng，湖南大学
标题：SNORD113-114 Cluster Maintains Hematopoietic Stem Cell Self-Renewal Via Orchestrating the Translation Machinery
报告人及单位：Hui Wang，浙江大学医学院附属第一医院
标题：Spatial Architecture of Immune Microenvironment Orchestrating Anti-Lymphoma Immunity and the Response to Immunochemotherapy in EBV+ Diffused Large B Cell Lymphoma Revealed By Imaging Mass Cytometry and Spatial Transcriptome
报告人及单位：林志娟，厦门大学附属第一医院
标题：Safety and Efficacy of Tgrx-678, a Potent BCR::ABL1 allosteric Inhibitor, in Patients with Tyrosine Kinase Inhibitor Resistant and/or Intolerant Chronic Myeloid Leukemia: Updated Results of Phase 1 Study Tgrx-678 -1001
报告人及单位：江倩，北京大学人民医院
标题：Olverembatinib As Second-Line (2L) Therapy in Patients (pts) with Chronic Phase-Chronic Myeloid Leukemia (CP-CML)
报告人及单位：黎纬明，华中科技大学同济医学院附属协和医院
标题：Rovadicitinib in Patients with Myelofibrosis Who Were Refractory or Relapsed or Intolerant to Ruxolitinib: A Single Arm, Multicenter, Open-Label, Phase Ib Study
报告人及单位：常春康，上海市第六人民医院
标题：First-in-Human Phase I/IIa Safety and Efficacy of Flonoltinib Maleate, a New Generation of JAK2/FLT3 Inhibitor in Myelofibrosis
报告人及单位：Lijuan Chen，四川大学华西医院
标题：Polycomb Repressive Complex 2 Regulates Differentiation-Stage-Specific Autophagy Gene Expression and Safeguards Normal Erythropoiesis
报告人及单位：Jiazhuo Li，广州市第一人民医院（华南理工大学附属第二医院）
标题：A Novel Role of LKB1 in Erythroblast Enucleation
报告人及单位：Yuanlin Xu，河南省肿瘤医院
标题：Procr+ Endothelial Progenitor Cells Modulate Adult Hematopoiesis and Microenvironment Homeostasis Via Notch Signaling
报告人及单位：Chang Xu，中国医学科学院血液病医院（中国医学科学院血液学研究所）
标题：Clinical Implications of CSF-Ctdna Positivity in Newly Diagnosed Diffuse Large B Cell Lymphoma in a Large Cohort
报告人及单位：梁金花，江苏省人民医院
标题：Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Improved Prognosis for Advanced NK/T Cell Lymphoma
报告人及单位：李智慧，北京高博博仁医院
标题：Decitabine Plus All-Trans Retinoic Acid Versus Decitabine Monotherapy for Myelodysplastic Syndromes with Excess Blasts: A Multicentre, Randomized Controlled Trial
报告人及单位：佟红艳，浙江大学医学院附属第一医院
标题：Safety and Efficacy of Bicistronic CD19/CD22 CAR T Cell Therapy in Childhood B Cell Acute Lymphoblastic Leukemia
报告人及单位：Hua Zhang，上药生物治疗(香港)有限公司
标题：CD19 CAR T-Cell Therapy in Refractory Autoimmune Hemolytic Anemia
报告人及单位：李若难，中国医学科学院血液病医院（中国医学科学院血液学研究所）
标题：Sequential Infusion of Anti-CD19 and Anti-BCMA Chimeric Antigen Receptor T-Cells: A Promising Treatment Strategy for Refractory Immune-Mediated Platelet Transfusion Refractoriness
报告人及单位：Yunju Ma，苏州大学附属第一医院
标题：Parvovirus B19 Originates from Infected Hematopoietic Stem Cells Following Hematopoietic Stem Cell Transplantation
报告人及单位：裴旭颖，北京大学人民医院
标题：Haploidentical Peripheral Blood Stem Cell Combined with Bone Marrow or Unrelated Cord Blood As Grafts for Acute Leukemia/Myelodysplastic Syndrome: An Open-Label, Multicenter, Randomized, Phase 3 Trial
报告人及单位：Sijian Yu，南方医科大学南方医院
标题：Preliminary Efficacy and Safety Results of TQB3473, a Novel Syk Inhibitor, in Adult Patients with Immune Thrombocytopenia (ITP)
报告人及单位：周虎，河南省肿瘤医院
标题：Updated Outcome from Biomarker MSC-C5b-9-Guided All-Trans Retinoic Acid Treatment for Resistant/Recurrent ITP: A Multicenter, Randomized, Open-Label, Phase 3 Clinical Trial
报告人及单位：李梦琳，北京大学人民医院
标题：Rovadicitinib in Patients with Hemophagocytic Lymphohistiocytosis: A Single Arm, Open-Label, Phase I Study
报告人及单位：王昭，首都医科大学附属北京友谊医院
标题：Pharmacological and Mechanism Study of a New RIPK1 Inhibitor Via Necroptosis to Treat Hemophagocytic Lymphohistiocytosis
报告人及单位：Jinbing Zhu，四川大学华西医院
标题：TENT5C As a Target of Chromatin Remodeler SMARCA2 Participates BTK Inhibitor Resistance in Mantle Cell Lymphoma By Regulating ATP Metabolism
报告人及单位：阎禹廷，中国医学科学院血液病医院（中国医学科学院血液学研究所）
标题：ST6GALNAC4 Promotes Diffuse Large B-Cell Lymphoma Progression Via Mediating Sialylation of Bmpr-1B at Thr24
报告人及单位：Yu Zhang，山东省立医院
标题：Venetoclax Combined with Hag Regimen in Newly Diagnosed ETP-ALL: A Prospective, Multicenter, Phase 2 Trial
报告人及单位：Shanshan Suo，浙江大学医学院附属第一医院
标题：Tucidinostat Plus Pediatric-Inspired Chemotherapy As First-Line Therapy for Newly Diagnosed ETP-ALL/Lbl: An Open-Label, Single-Arm, Phase 2 Trial
报告人及单位：Jieping Lin，南方医科大学南方医院
标题：The Mutated of KRAS gene Determine the Fate of KMT2A-Rearranged AML Patients
报告人及单位：吴一波，浙江大学医学院附属第一医院
标题：CD38 Overexpressed Monocytes Play a Critical Role in the Fibrogenesis in Myeloproliferative Neoplasms and Can be Used As a Therapeutic Target to Ameliorate Fibrosis
报告人及单位：李冰，中国医学科学院血液病医院（中国医学科学院血液学研究所）
标题：Venetoclax Plus Dexamethasone As First-Line Treatment for t(11; 14) Light-Chain Amyloidosis: Preliminary Result of a Phase II Prospective, Multicenter, Single-Arm Study
报告人及单位：Kaini Shen，北京协和医院
标题：CD33 Antibody-Modified Nanoparticles Encapsulated IL-15 Induce ISG15 to Promote MHC I Expression in Leukemia Cells Via Innate Immunity Pathway Inducing Graft-Versus-Leukemia without Aggravating Graft-Versus-Host Disease
报告人及单位：Ruowen Wei，华中科技大学同济医学院附属协和医院
标题：A Novel Generation of Anti-CD7 Universal CAR-T Therapy for Patients with Relapsed or Refractory CD7 Positive T-ALL/Lbl: A Phase I Clinical Trial
报告人及单位：胡永仙，浙江大学医学院附属第一医院
标题：A Prospective Investigator-Initiated Phase 1/2 Study of BCMA/CD19 Dual-Targeting CAR T Therapy in Patients with Relapsed/Refractory Multiple Myeloma Including Those with Extramedullary Disease
报告人及单位：姜华，上海第四人民医院
标题：A Highly Selective and Orally Bioavailable CK1α Molecular Glue Degrader Targets B-Cell Lymphoma Cells
报告人及单位：Ran Kong，山东省立医院
标题：KPT-330 Combined with Radiation Therapy: Effective Central Nervous System Lymphoma Treatment with Reduced Neurotoxicity
报告人及单位：李炳宗，苏州大学附属第二医院
标题：CD93+ Myeloid Cells Suppress T-Cell-Mediated Anti-Tumor Immunity
报告人及单位：于慧，北京大学肿瘤医院
标题：CD7 CAR T-Cell Therapy in Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia: A Retrospective Study
报告人及单位：潘静 ，北京高博博仁医院
标题：Venetoclax and Decitabine Compared with Standard Intensive Chemotherapy As Induction Therapy in Newly Diagnosed Acute Myeloid Leukemia: Updated Results of a Multicenter, Randomized, Phase 2b Trial
报告人及单位：Jing Lu，苏州大学附属第一医院
标题：High-Dose Cytarabine with Idarubicin Versus High-Dose Cytarabine within First Consolidation for Acute Myeloid Leukemia in First Complete Remission: An Open-Label, Multicenter, Randomized, Phase 3 Trial
报告人及单位：Zinan Feng，南方医科大学南方医院
标题：Faecalibacterium Prausnitzii Confers a Protective Effect Against the Development of NKTCL
报告人及单位：Zhuangzhuang Shi，郑州大学第一附属医院
标题：Final Analysis of a Phase 1 Study of Zanubrutinib Plus Lenalidomide in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
报告人及单位：宋拯，天津医科大学肿瘤医院
标题：The Efficacy and Safety of Selinexor in Combination with Ruxolitinib in Ruxolitinib-Treated Myelofibrosis Patients: The Interim Analysis of a Prospective, Open-Label, Multicenter, Parallel-Cohort, Phase 2 Study
报告人及单位：段明辉，北京协和医院
标题：A Single-Center, Single-Arm, Phase I Clinical Trial of Anti-BCMA/GPRC5D Bispecific CAR T-Cells in Patients with Refractory and Relapsed Multiple Myeloma with Extramedullary Disease
报告人及单位：邱玲，中国人民解放军西部战区总医院
标题：A Multicenter Randomized Controlled Trial of Low-Dose Ruxolitinib for Gvhd Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplantation
报告人及单位：Hengwei Wu，浙江大学医学院附属第一医院
标题：Mini-Dosed Blinatumomab Maintenance Therapy Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute B-Cell Lymphoblastic Leukemia
报告人及单位：季杰，四川大学华西医院
标题：Updated Results from a Phase Ⅱ Clinical Trial：Safety and Efficacy of Azacitidine and Chidamide Maintenance after Allogeneic Hematopoietic Stem Cell Transplantation for Patients with High-Risk Acute Myeloid Leukemia
报告人及单位：黄睿，南方医科大学珠江医院
排名不分先后，按照摘要号进行排序，
本文纳入了报告人单位所属地为中国的研究，
如有遗漏或任何问题，请给我们留言~
